Signaling pathways activated by the B-cell receptor in chronic lymphocytic leukemia

Expert Review of Hematology

Volumn 5, Issue 3, 2012, Pages 341-348

  Scupoli, Maria Teresa ^a,b   Pizzolo, Giovanni ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

apoptosis; B cell; BCR; cell proliferation; cell signaling; microenvironment

Indexed keywords

B LYMPHOCYTE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE ZAP 70;

APOPTOSIS; CELL DIVISION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG TARGETING; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

ANIMALS; B-LYMPHOCYTES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULAR TARGETED THERAPY; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 84863807029     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.12.21     Document Type: Review

References (79)

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N. Engl. J. Med. 333(16), 1052-1057 (1995).
2. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94(6), 1848-1854 (1999).
3. Damle RN, Wasil T, Fais F et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94(6), 1840-1847 (1999).
4. Döhner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343(26), 1910-1916 (2000).
5. Crespo M, Bosch F, Villamor N et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. 348(18), 1764-1775 (2003).
6. Burger JA, Gandhi V. The lymphatic tissue microenvironments in chronic lymphocytic leukemia: In vitro models and the significance of CD40-CD154 interactions. Blood 114(12), 2560-2561; author reply 2561 (2009).
7. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: Lessons learned from studies of the B cell antigen receptor. Annu. Rev. Immunol. 21, 841-894 (2003).
8. Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 118(16), 4313-4320 (2011).
9. Reth M. Antigen receptor tail clue. Nature 338(6214), 383-384 (1989).
10. Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B cell antigen receptor signaling 101. Mol. Immunol. 41(6-7), 599-613 (2004).
11. Kurosaki T. Regulation of B-cell signal transduction by adaptor proteins. Nat. Rev. Immunol. 2(5), 354-363 (2002).
12. Reth M, Wienands J. Initiation and processing of signals from the B cell antigen receptor. Annu. Rev. Immunol. 15, 453-479 (1997).
13. Scharenberg AM, Humphries LA, Rawlings DJ. Calcium signalling and cell-fate choice in B cells. Nat. Rev. Immunol. 7(10), 778-789 (2007).
14. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu. Rev. Immunol. 20, 55-72 (2002).
15. Saijo K, Mecklenbräuker I, Santana A, Leitger M, Schmedt C, Tarakhovsky A. Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha. J. Exp. Med. 195(12), 1647-1652 (2002).
16. Crabtree GR, Olson EN. NFAT signaling: Choreographing the social lives of cells. Cell 109(Suppl.), S67-S79 (2002).
17. Tedder TF, Inaoki M, Sato S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 6(2), 107-118 (1997).
18. Fujimoto M, Fujimoto Y, Poe JC et al. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 13(1), 47-57 (2000).
19. Tuveson DA, Carter RH, Soltoff SP, Fearon DT. CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science 260(5110), 986-989 (1993).
20. Downward J. PI3-kinase, Akt and cell survival. Semin. Cell Dev. Biol. 15(2), 177-182 (2004).
21. Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF-kappaB by the Akt/PKB kinase. Curr. Biol. 9(11), 601-604 (1999).
22. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401(6748), 82-85 (1999).
23. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401(6748), 86-90 (1999).
24. Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem. J. 441(1), 1-21 (2012).
25. Nagaoka H, Takahashi Y, Hayashi R et al. Ras mediates effector pathways responsible for pre-B cell survival, which is essential for the developmental progression to the late pre-B cell stage. J. Exp. Med. 192(2), 171-182 (2000).
26. Oh-hora M, Johmura S, Hashimoto A, Hikida M, Kurosaki T. Requirement for Ras guanine nucleotide releasing protein 3 in coupling phospholipase C-gamma2 to Ras in B cell receptor signaling. J. Exp. Med. 198(12), 1841-1851 (2003).
27. Zheng Y, Liu H, Coughlin J, Zheng J, Li L, Stone JC. Phosphorylation of RasGRP3 on threonine 133 provides a mechanistic link between PKC and Ras signaling systems in B cells. Blood 105(9), 3648-3654 (2005).
28. Ingley E. Src family kinases: Regulation of their activities, levels and identification of new pathways. Biochim. Biophys. Acta 1784(1), 56-65 (2008).
29. Gobessi S, Laurenti L, Longo PG et al. Inhibition of constitutive and BCRinduced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 23(4), 686-697 (2009).
30. Herishanu Y, Pérez-Galán P, Liu D et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117(2), 563-574 (2011).
31. Hewamana S, Alghazal S, Lin TT et al. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 111(9), 4681-4689 (2008).
32. Muzio M, Apollonio B, Scielzo C et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: A molecular signature of anergy. Blood 112(1), 188-195 (2008).
33. Stadanlick JE, Kaileh M, Karnell FG et al. Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling. Nat. Immunol. 9(12), 1379-1387 (2008).
34. Chen L, Widhopf G, Huynh L et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 100(13), 4609-4614 (2002).
35. Allsup DJ, Kamiguti AS, Lin K et al. B-cell receptor translocation to lipid rafts and associated signaling differ between prognostically important subgroups of chronic lymphocytic leukemia. Cancer Res. 65(16), 7328-7337 (2005).
36. Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 101(3), 1087-1093 (2003).
37. Petlickovski A, Laurenti L, Li X et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 105(12), 4820-4827 (2005).
38. Gauld SB, Merrell KT, Cambier JC. Silencing of autoreactive B cells by anergy: A fresh perspective. Curr. Opin. Immunol. 18(3), 292-297 (2006).
39. Packham G, Stevenson F. The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia. Semin. Cancer Biol. 20(6), 391-399 (2010).
40. Krysov S, Dias S, Paterson A et al. Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells. Blood 119(1), 170-179 (2012).
41. Zupo S, Massara R, Dono M et al. Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. Blood 95(4), 1199-1206 (2000).
42. Deglesne PA, Chevallier N, Letestu R et al. Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression. Cancer Res. 66(14), 7158-7166 (2006).
43. Guarini A, Chiaretti S, Tavolaro S et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood 112(3), 782-792 (2008).
44. Pallasch CP, Schulz A, Kutsch N et al. Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease. Blood 112(10), 4213-4219 (2008).
45. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 111(2), 846-855 (2008).
46. Bernal A, Pastore RD, Asgary Z et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 98(10), 3050-3057 (2001).
47. Schimmer AD, Munk-Pedersen I, Minden MD, Reed JC. Bcl-2 and apoptosis in chronic lymphocytic leukemia. Curr. Treat. Options Oncol. 4(3), 211-218 (2003).
48. Cuní S, Pérez-Aciego P, Pérez-Chacón G et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 18(8), 1391-1400 (2004).
49. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NFkappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J. Immunol. 164(4), 2200-2206 (2000).
50. Hewamana S, Lin TT, Rowntree C et al. Rel A is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. J. Clin. Oncol. 27(5), 763-769 (2009).
51. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends Biochem. Sci. 36(6), 320-328 (2011).
52. Scupoli MT, Perbellini O, Cioffi F et al. BCR-signaling profiles associated with prognosis and progression in B-CLL. Presented at: 15th Congress of the European Hematology Association. Barcelona, Spain, 10-13 June 2010.
53. Cesano A, Evensen E, Ptacek J et al. BCR responsiveness is associated with time to first treatment (TTFT) in B-cell chronic lymphocytic leukemia (B-CLL): Results from a Single Cell Network Profiling (SCNP) verification study. Presented at: 53rd ASH Annual Meeting. San Diego, CA, USA, 10-13 December 2011.
54. Datta SR, Dudek H, Tao X et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91(2), 231-241 (1997).
55. Liu H, Perlman H, Pagliari LJ, Pope RM. Constitutively activated Akt-1 is vital for the survival of human monocytedifferentiated macrophages. Role of Mcl-1, independent of nuclear factor (NF)-kappaB, Bad, or caspase activation. J. Exp. Med. 194(2), 113-126 (2001).
56. Kitada S, Andersen J, Akar S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses. Blood 91(9), 3379-3389 (1998).
57. Messmer BT, Messmer D, Allen SL et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J. Clin. Invest. 115(3), 755-764 (2005).
58. Bechter OE, Eisterer W, Pall G, Hilbe W, Kühr T, Thaler J. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Res. 58(21), 4918-4922 (1998).
59. Nédellec S, Renaudineau Y, Bordron A et al. B cell response to surface IgM cross-linking identifies different prognostic groups of B-chronic lymphocytic leukemia patients. J. Immunol. 174(6), 3749-3756 (2005).
60. Weinblatt ME, Kavanaugh A, Burgos-Vargas R et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: A twelve-week, randomized, placebocontrolled trial. Arthritis Rheum. 58(11), 3309-3318 (2008).
61. Klein U, Tu Y, Stolovitzky GA et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J. Exp. Med. 194(11), 1625-1638 (2001).
62. Ghia P, Caligaris-Cappio F. The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. Adv. Cancer Res. 79, 157-173 (2000).
63. Fais F, Ghiotto F, Hashimoto S et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J. Clin. Invest. 102(8), 1515-1525 (1998).
64. Ghia P, Chiorazzi N, Stamatopoulos K. Microenvironmental influences in chronic lymphocytic leukaemia: The role of antigen stimulation. J. Intern. Med. 264(6), 549-562 (2008).
65. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: Revelations from the B-cell receptor. Blood 103(12), 4389-4395 (2004).
66. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N. Engl. J. Med. 352(8), 804-815 (2005).
67. Mockridge CI, Potter KN, Wheatley I, Neville LA, Packham G, Stevenson FK. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 109(10), 4424-4431 (2007).
68. Braselmann S, Taylor V, Zhao H et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J. Pharmacol. Exp. Ther. 319(3), 998-1008 (2006).
69. Friedberg JW, Sharman J, Sweetenham J et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115(13), 2578-2585 (2010).
70. Spaargaren M, Beuling EA, Rurup ML et al. The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J. Exp. Med. 198(10), 1539-1550 (2003).
71. De Gorter DJ, Beuling EA, Kersseboom R et al. Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 26(1), 93-104 (2007).
72. Honigberg LA, Smith AM, Sirisawad M et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107(29), 13075-13080 (2010).
73. Burger JA. Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. Curr. Hematol. Malig. Rep. 7(1), 26-33 (2012).
74. Burger JA, O'Brien S, Fowler N et al. The Bruton's tyrosine kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinicalactivity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): An updateon ongoing Phase 1 studies. Presented at: 52nd ASH Annual Meeting. Orlando, FL, USA, 4-7 December 2010.
75. Advani R, Sharman JP, Smith SM et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a Phase I study. J. Clin. Oncol. 28(Suppl. 15), 8012 (2010).
76. Herman SE, Gordon AL, Hertlein E et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117(23), 6287-6296 (2011).
77. Ponader S, Chen SS, Buggy JJ et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119(5), 1182-1189 (2012).
78. Furman RR, Byrd JC, Brown JR et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Presented at: 52nd ASH Annual Meeting. Orlando, FL, USA, 4-7 December 2010.
79. Hoellenriegel J, Meadows SA, Sivina M et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118(13), 3603-3612 (2011).